Gene therapy is finally poised to make a contribution to the treatment of debilitating, highly penetrant genetic diseases that have proved intractable to other regimens.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
High-throughput 5′ UTR engineering for enhanced protein production in non-viral gene therapies
Nature Communications Open Access 06 July 2021
-
Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus
Translational Psychiatry Open Access 04 May 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
12 April 2011
In the version of the article originally published, Table 1 left off AAV as a section heading. A number of products listed under Adenovirus should have been listed under AAV. Neurologix product NLXP10 was incorrectly listed under the heading of retrovirus, and in phase 2 of development. It should be listed under the heading AAV, and the phase of development should have read phase 2 completed. The errors have been corrected in the HMTL and PDF versions of the article.
References
Friedmann, T. Nat. Genet. 2, 93–98 (1992).
Friedmann, T. & Roblin, R. Science 175, 949–955 (1972).
Anonymous. Nat. Med. 6, 1 (2000).
Hacein-Bey-Abina, S. et al. J. Clin. Invest. 118, 3132–3142 (2008).
Fischer, A. et al. Nat. Immunol. 11, 457–460 (2010).
http://storm.zoomvisionmamato.com/player/diamyd_medical/objects/7c8rv49g/ (Accessed 26 October 2010).
Mitomo, K. et al. Mol. Ther. 18, 1173–1182 (2010).
Aiuti, A. et al. N. Engl. J. Med. 360, 447–458 (2009).
Naldini, L. et al. Science 272, 263–267 (1996).
Bartus, R.T. et al. Mov. Disord. published online, doi: 10.1002/mds.23442 (18 November 2010).
Lock, M. et al. Hum. Gene Ther. 21, 1273–1285 (2010).
Friedmann, T. Nat. Genet. 2, 93–98 (1992).
Wade, N. Science 212, 24–25 (1981).
Blaese, R.M. et al. Science 270, 475–480 (1995).
Bordignon, C. et al. Science 270, 470–475 (1995).
Branca, M.A. Nat. Biotechnol. 23, 519–521 (2005).
Cavazzana-Calvo, M. et al. Science 288, 669–672 (2000).
Guo, J. & Xin, H. Science 314, 1232–1235 (2006).
Levine, B.L. et al. Proc. Natl. Acad. Sci. USA 103, 17372–17377 (2006).
Maguire, A.M. et al. Lancet 374, 1597–1605 (2009).
Cavazzana-Calvo, M. et al. Nature 467, 318–322 (2010).
Hyde, S.C. et al. Nat. Biotechnol. 26, 549–551 (2008).
Akinc, A. et al. Nat. Biotechnol. 26, 561–569 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Gene therapy finds its niche. Nat Biotechnol 29, 121–128 (2011). https://doi.org/10.1038/nbt.1769
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1769
This article is cited by
-
Current advances and future prospects in production of recombinant insulin and other proteins to treat diabetes mellitus
Biotechnology Letters (2022)
-
High-throughput 5′ UTR engineering for enhanced protein production in non-viral gene therapies
Nature Communications (2021)
-
When is it Safe to Edit the Human Germline?
Science and Engineering Ethics (2021)
-
Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus
Translational Psychiatry (2020)